Heart Attack

HeroMD 4-MAX Claims Evaluated: Why Men Searching “Most Effective 4-in-1 Erectile Dysfunction Formula” Are Comparing SURGE, PRIME and The HERO System Explained

Staff June 14, 2026

Sublingual Compounded Vardenafil, Sildenafil, Tadalafil, and Apomorphine for Prescription ED Treatment: 10-Minute Onset and 36-Hour Active Window ResearchedKennewick, WA, June...

Medmovie Launches HxHeart.com, Bringing Its Trusted Cardiovascular Education Library to Any Browser — and Releases a New Video on the Hidden Risks of Coronary Artery Disease

Staff June 10, 2026

The same clinician-approved animations from the Hx Heart app are now available online at HxHeart.com — free, instantly, with no...

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Staff June 3, 2026

Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion...

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Staff May 31, 2026

– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants...

Aspire Biopharma Issues Shareholder Letter

Staff May 28, 2026

ESTERO, FL / ACCESS Newswire / May 28, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a...

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

Staff May 27, 2026

DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to...

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Staff May 19, 2026

Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide's favourable hepatic profile in patients with Metabolic Dysfunction-associated Steatohepatitis (MASH),...

CVS Health: A Second Chance at Life Through Heart Transplant and Ongoing Care

Staff May 18, 2026

WOONSOCKET, RI / ACCESS Newswire / May 18, 2026 / Originally published on CVS Health Company NewsroomKey pointsAfter smoking for...

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Staff May 7, 2026

Official FDA meeting minutes and Phase 2 data provide guidance on the pivotal Phase 3 registration path for CAD-1005 in...

Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity

Staff April 28, 2026

Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast...

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

Staff April 27, 2026

ESTERO, FL / ACCESS Newswire / April 27, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a...

GB HealthWatch Launches AI-Ready Genetic Reports for the GB Longevity100 Suite

Staff April 23, 2026

AI-powered innovation transforms complex genetic data into clear, actionable insights for clinicians and individuals Genomics + AI for Longevity Transforming...

Press Release: ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

Staff April 18, 2026

ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study First head-to-head, double-blind, randomized phase 4 study...

Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU

Staff April 9, 2026

The European Medicines Agency (EMA) has approved an update to the product information of Wegovy® injection, allowing it to be...

American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction

Staff April 8, 2026

DUBLIN and BRIDGEWATER, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to...

How Decentralized AI is Unlocking Value in Cardiac Diagnostics

Staff March 27, 2026

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.VANCOUVER,BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – Heart disease is a...

Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline

Staff March 18, 2026

DUBLIN and BRIDGEWATER, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin”), a company committed to...

New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo

Staff March 16, 2026

DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing...

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

Staff March 12, 2026

PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments...

Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates

Staff March 9, 2026

Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 ...